Human papillomavirus genotyping results of human papillomavirus vaccinated women of reproductive age


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To determine the most common types of human papillomavirus (HPV) involved in the neoplastic transformation of the cervical epithelium in HPV vaccinated women of reproductive age. Materials and methods. The study included 3 groups with 141 patients. Group 1 (HPV vaccinated) included 62 patients (average age of 31 years). This group was divided into 2 subgroups: patients vaccinated before sexual activity (n=26, 41.9%) were enrolled in subgroup 1a and women vaccinated after sexual activity (n=36, 58.06%) were in subgroup 1b. Group 2 included patients with the cytological diagnosis of high-grade squamous intraepithelial lesions (HSIL) (n=42), group 3 included patients negative for intraepithelial lesion or malignancy (NILM) (controlgroup, n=37). A comprehensive clinical and laboratory examination was carried out, including HPV typing, cytological examination. Results. Among them, 76 (53.9%) patients were HPV-positive: 100% in the HSIL group, 54% in the NILMgroup and 22.5% in the vaccinated group (38.8% in subgroup 1b and 0% in subgroup 1a). HPV vaccine types were statistically significantly less identified in group 1 (vaccinated) - 6.4%, compared to group 2 (HSIL) (29.7%) (p<0.05). In group 1 the most common type of HPV was HPV 56 (4.2%), in groups 2 and 3, HPV type 16 was the most common one with 21.9% and 4.96%, respectively. Conclusion. HPV of group 1 (carcinogenic) A9 and A7 were significantly less common in patients of group 1 compared to unvaccinated patients of groups 2 and 3.

Full Text

Restricted Access

About the authors

Kirill I. Gusakov

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: kigusakov@gmail.com
MD, pre-PhD

Niso M. Nazarova

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: grab2@yandex.ru
MD, senior research fellow

Vladimir E. Frankevich

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: v_frankevich@oparina4.ru
PhD, Head of Department of Systems Biology in Reproduction

Nataliia L. Starodubtseva

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: n_starodubtseva@oparina4.ru
PhD, Head of Laboratory of Proteomics of Human Reproduction

Olga V. Burmenskaya

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: o_bourmenskaya@oparina4.ru
PhD, senior researcher, Laboratory of Molecular Genetic Methods

Vera N. Prilepskaya

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: vprilepskaya@mail.ru
PhD, Professor, Deputy Director for Science

Gennady T. Sukhikh

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

academician RAS, MD, PhD, Director

References

  1. Сычева Е.Г., Назарова Н.М., Бурменская О.В., Прилепская В.Н., Трофимов Д.Ю., Сухих Г.Т. Персистенция ВПЧ высокого онкогенного риска и другие молекулярно-генетические предикторы развития цервикальных интраэпителиальных неоплазий. Акушерство и гинекология. 2018; 12: 104-10
  2. WHO. Global Cancer Observatory. Lyon: International Agency for Research on Cancer; March 2019.
  3. Bruni L., Albero G., Serrano B., Mena M., Gomez D., Munoz J., Bosch F.X., de Sanjose S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in Russian Federation. Summary Report 17. June 2019.
  4. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИРЦ" Минздрава России. 2019. Available at: http://www.oncology.ru/service/statistics/ malignant_tumors/2018.pdf
  5. Human Papillomavirus (HPV) Vaccine. Merck Sharp; Dohme. August 2019. Available at: https://www.msdmanuals.com/home/infections/immunization/ human-papillomavirus-hpv-vaccine
  6. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. U.S. Food & Drug Administration. 5 October 2018.
  7. ARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs, Volume 100 (B). 2012.
  8. de Villiers E.M. Cross-roads in the classification of papillomaviruses. Virology. 2013; 445(1-2): 2-10. https://dx.doi.org/10.1016/j.virol.2013.04.023.
  9. Arbyn M., Tommasino M., Depuydt C., Dillner J. Are 20 human papillomavirus types causing cervical cancer? J. Pathol. 2014; 234(4): 431-5. https://dx.doi. org/10.1002/path.4424.
  10. Nayar R., Wilbur D. The Bethesda system for reporting cervical cytology. Definitions, criteria, and explanatory notes. January 2015. https://dx.doi. org/10.1007/978-3-319-11074-5.
  11. Paz-Zulueta M., Alvarez-Paredes L., Rodriguez Diaz J.C., Paras-Bravo P., Andrada Becerra M.E., Rodriguez Ingelmo J.M. et al. Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. BMC Cancer. 2018; 18(1): 112. https://dx.doi.org/10.1186/s12885-018-4033-2.
  12. Jeannot E., Viviano M., de Pree C., Amadane M., Kabengele E., Vassilakos P., Petignat P. Prevalence of vaccine type infections in vaccinated and nonvaccinated young women: HPV-IMPACT, a Self-Sampling Study. Int. J. Environ. Res. Public Health. 2018; 15(7): 1447. https://dx.doi.org/10.3390/ ijerph15071447.
  13. Shilling H., Murray G., Brotherton J.M.L., Hawkes D., Saville M., Sivertsen T. et al. Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening. Vaccine. 2020; 38(5): 1186-93. https://dx.doi.org/10.1016/j.vaccine.2019.11.019.
  14. Lehtinen M., Lagheden C., Luostarinen T., Eriksson T., Apter D., Harjula K. et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. BMJ Open. 2017; 7(8): e015867. https://dx.doi. org/10.1136/bmjopen-2017-015867.
  15. World Health Organization. Wkly Epidemiol. Rec. 2014; 21.
  16. D'Addario M., Redmond S., Scott P., Egli-Gany D., Riveros-Balta A.X., Henao Restrepo A.M., Low N. Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis. Vaccine. 2017; 35(22): 2892-901. https:// dx.doi.org/10.1016/j.vaccine.2017.03.096.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies